BC
MRTX

Bridgefront Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bridgefront Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,139
Closed -$202K – 475
2021
Q3 		$202K Buy
+1,139
New +$183K 0.21% 246
2021
Q1 		– Sell
-3,739
Closed -$821K – 971
2020
Q4 		$821K Buy
+3,739
New +$808K 0.28% 91

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Bridgefront Capital's MRTX Position: Q4 2021 in Review

Bridgefront Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2021, closing a stake of 1,139 shares — an estimated $202K sold.

Bridgefront Capital first reported a position in MRTX in Q4 2020 and held it in 2 quarters. The position peaked at $821K in Q4 2020. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

  • Bridgefront Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Bridgefront Capital sold 1,139 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $202K.
  • Bridgefront Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Bridgefront Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $821K in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Bridgefront Capital's 13F filing for Q4 2021, filed 10 Feb 2022.